Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms GRID
  • Sponsors Bayer; Bayer HealthCare

Most Recent Events

  • 03 Dec 2021 Data was used from trials (PAZOGIST & GRID) to assess cost-effectiveness of pazopanib versus regorafenib as a third-line treatment for metastatic or unresectable gastrointestinal stromal tumors in Chinapresented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 01 May 2020 Results from NCT01103323; NCT01271712; NCT01584830; NCT01774344 evaluating Population pharmacokinetics of regorafenib in solid tumors in clinical practice considering enterohepatic circulation and food intake, published in the British Journal of Clinical Pharmacology
  • 08 May 2019 This trial has been completed in Germany, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top